Melanie Wosnitza
Overview
Explore the profile of Melanie Wosnitza including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
114
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Khanna D, Kramer F, Hofler J, Ghadessi M, Sandner P, Allanore Y, et al.
Rheumatology (Oxford)
. 2024 Mar;
63(11):3124-3134.
PMID: 38460548
Objective: To examine disease and target engagement biomarkers in the RISE-SSc trial of riociguat in early diffuse cutaneous systemic sclerosis and their potential to predict the response to treatment. Methods:...
2.
Distler O, Allanore Y, Denton C, Kuwana M, Matucci-Cerinic M, Pope J, et al.
Lancet Rheumatol
. 2024 Jan;
5(11):e660-e669.
PMID: 38251533
Background: The phase 2b Riociguat Safety and Efficacy in Patients with Diffuse Cutaneous Systemic Sclerosis (RISE-SSc) trial investigated riociguat versus placebo in early diffuse cutaneous systemic sclerosis. The long-term extension...
3.
Dicpinigaitis P, Morice A, Smith J, Sher M, Vaezi M, Guilleminault L, et al.
Lung
. 2023 Jun;
201(3):255-266.
PMID: 37261531
Introduction: The PAGANINI study evaluated the efficacy and safety of the selective P2X3 antagonist eliapixant in patients with refractory chronic cough (RCC). Methods: PAGANINI was a randomized, double-blind, parallel-group, placebo-controlled,...
4.
Cappato R, Ezekowitz M, Hohnloser S, Meng I, Wosnitza M, Camm A
Europace
. 2021 Jun;
23(10):1539-1547.
PMID: 34128075
Aims: Using a pre-planned post hoc analysis of patients included in X-VeRT, we evaluated predictors of sinus rhythm at 6 weeks after planned cardioversion. Methods And Results: Receiver operating characteristic...
5.
Henry M, Wosnitza M, Thate-Waschke I, Bauersachs R, Ueng K, Chang K, et al.
J Cardiovasc Pharmacol
. 2020 Nov;
77(1):100-106.
PMID: 33165142
The aim of this study was to examine atrial fibrillation (AF) patients' preferences regarding oral anticoagulation (OAC) characteristics and to investigate differences across 5 different countries. A multicenter discrete choice...
6.
Khanna D, Allanore Y, Denton C, Kuwana M, Matucci-Cerinic M, Pope J, et al.
Ann Rheum Dis
. 2020 Apr;
79(5):618-625.
PMID: 32299845
Objectives: Riociguat is approved for pulmonary arterial hypertension and has antiproliferative, anti-inflammatory and antifibrotic effects in animal models of tissue fibrosis. We evaluated the efficacy and safety of riociguat in...
7.
Kirchhof P, Ezekowitz M, Purmah Y, Schiffer S, Meng I, Camm A, et al.
TH Open
. 2020 Jan;
4(1):e20-e32.
PMID: 31984306
This X-VeRT (eXplore the efficacy and safety of once-daily oral riVaroxaban for the prevention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion) substudy evaluated the effects...
8.
Heise R, Skazik C, Rodriguez F, Stanzel S, Marquardt Y, Joussen S, et al.
J Invest Dermatol
. 2009 Jul;
130(1):305-8.
PMID: 19587694
No abstract available.
9.
Wosnitza M, Hemmrich K, Groger A, Graber S, Pallua N
Differentiation
. 2007 Jan;
75(1):12-23.
PMID: 17244018
Recent research findings postulate that adipocytes and endothelial cells (EC) may share a common progenitor. However, the interlinking pathways between adipose tissue and endothelium, and the differentiation potential of cells...